PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 69.99

Change

-0.84 (-1.19)%

Market Cap

N/A

Volume

0.24M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.96 (-1.01%)

USD 88.29B
HLN Haleon plc

-0.15 (-1.40%)

USD 48.57B
TAK Takeda Pharmaceutical Co Ltd A..

+0.04 (+0.28%)

USD 45.08B
RDY Dr. Reddy’s Laboratories Ltd..

-0.36 (-0.45%)

USD 13.46B
CTLT Catalent Inc

+0.22 (+0.37%)

USD 10.91B
ELAN Elanco Animal Health

-0.06 (-0.41%)

USD 7.26B
BHC Bausch Health Companies Inc

-0.11 (-1.33%)

USD 3.00B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.11 (-1.26%)

USD 2.66B
CPHI China Pharma Holdings Inc

+0.03 (+15.25%)

USD 3.66M
YCBD cbdMD Inc

N/A

USD 1.73M

ETFs Containing PBH

NDIA Global X Funds 3.75 % 0.00 %

-0.10 (-0.31%)

USD 0.01B
XST:CA iShares S&P/TSX Capped Co.. 0.00 % 0.61 %

-0.50 (-0.31%)

CAD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.33% 69% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.33% 56% F 61% D-
Trailing 12 Months  
Capital Gain 22.47% 63% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.47% 56% F 49% F
Trailing 5 Years  
Capital Gain 98.84% 80% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 98.84% 80% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.15% N/A N/A 80% B-
Dividend Return 16.15% N/A N/A 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.25% N/A N/A 49% F
Risk Adjusted Return 76.01% N/A N/A 87% B+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector